Metabolic effects of aldosterone

Q3 Medicine

Obesity and Metabolism Pub Date : 2024-01-22 DOI:10.14341/omet13040

K. V. Ivashchenko, N. V. Mazurina, N. M. Platonova, E. A. Troshina

{"title":"Metabolic effects of aldosterone","authors":"K. V. Ivashchenko, N. V. Mazurina, N. M. Platonova, E. A. Troshina","doi":"10.14341/omet13040","DOIUrl":null,"url":null,"abstract":"Currently, increasing evidence shows the mutual influence of aldosterone and adipose tissue. Aldosterone excess has been reported in patients with obesity and metabolic syndrome. Aldosterone has a direct effect on adipose tissue increasing anabolic activity and expression of mineralocorticoid receptors. In turn, excessive activation of MCR leads to stimulation of adipogenesis and an increase in the volume of adipose tissue. Aldosterone excess can be considered an independent cardiovascular risk factor that affects such processes as cardiac fibrosis, nephrosclerosis, and arteriosclerosis. There is convincing evidence of higher prevalence and severity of impaired glucose homeostasis and lipid metabolism disorders among patients with primary hyperaldosteronism. Similar pathological changes are also observed in patients with obesity and metabolic syndrome. This review presents scientific data on the metabolic effects of aldosterone, in particular its effect on adipose tissue function, glucose and lipid metabolism. Treatment with mineralocorticoid receptor antagonists may provide substantial benefit in the management of metabolic syndrome, contribute to the stabilisation of glucose and lipid metabolism, improve clinical status of patients with cardiovascular diseases and reduce the risk of complications. However, available evidence from the conducted studies is not sufficient to justify introduction of such therapy into clinical practice.","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":"49 24","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/omet13040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Currently, increasing evidence shows the mutual influence of aldosterone and adipose tissue. Aldosterone excess has been reported in patients with obesity and metabolic syndrome. Aldosterone has a direct effect on adipose tissue increasing anabolic activity and expression of mineralocorticoid receptors. In turn, excessive activation of MCR leads to stimulation of adipogenesis and an increase in the volume of adipose tissue. Aldosterone excess can be considered an independent cardiovascular risk factor that affects such processes as cardiac fibrosis, nephrosclerosis, and arteriosclerosis. There is convincing evidence of higher prevalence and severity of impaired glucose homeostasis and lipid metabolism disorders among patients with primary hyperaldosteronism. Similar pathological changes are also observed in patients with obesity and metabolic syndrome. This review presents scientific data on the metabolic effects of aldosterone, in particular its effect on adipose tissue function, glucose and lipid metabolism. Treatment with mineralocorticoid receptor antagonists may provide substantial benefit in the management of metabolic syndrome, contribute to the stabilisation of glucose and lipid metabolism, improve clinical status of patients with cardiovascular diseases and reduce the risk of complications. However, available evidence from the conducted studies is not sufficient to justify introduction of such therapy into clinical practice.

查看原文本刊更多论文

醛固酮对代谢的影响

目前，越来越多的证据表明醛固酮与脂肪组织之间存在相互影响。据报道，肥胖症和代谢综合征患者体内醛固酮过多。醛固酮对脂肪组织有直接影响，可增加同化活性和矿质皮质激素受体的表达。反过来，MCR 的过度激活又会刺激脂肪生成，增加脂肪组织的体积。醛固酮过量可被视为一个独立的心血管风险因素，会影响心脏纤维化、肾硬化和动脉硬化等过程。有令人信服的证据表明，原发性醛固酮过多症患者的糖稳态受损和脂质代谢紊乱的发生率和严重程度更高。在肥胖症和代谢综合征患者中也可观察到类似的病理变化。本综述介绍了醛固酮对代谢影响的科学数据，特别是其对脂肪组织功能、葡萄糖和脂质代谢的影响。使用矿质皮质激素受体拮抗剂治疗代谢综合征可能大有裨益，有助于稳定血糖和血脂代谢，改善心血管疾病患者的临床状况，降低并发症风险。然而，现有的研究证据还不足以证明将这种疗法引入临床实践是正确的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity and Metabolism Medicine-Internal Medicine

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Journal "Obesity and Metabolism" is a multidisciplinary forum for clinical and applied research in the field of biochemistry, physiology, pathophysiology, genetics, nutrition, as well as molecular, metabolic, psychological and epidemiological aspects of obesity and metabolism. The main subject "Metabolism" reviewed in the journal, includes fat, carbohydrate, protein, bone, fluid and electrolyte and other types of metabolism in the spectrum of pathology of the endocrine system. The priority direction of Journal "Obesity and Metabolism" is publishing modern high-quality original research on the effectiveness of new and existing treatments in any aspect of metabolic and endocrine diseases. Pre-clinical pharmacology, pharmacokinetics studies, meta-analyzes, addressed to drug safety and tolerance are also welcome for publication in the journal "Obesity and metabolism." Journal "Obesity and Metabolism" announces review articles that are balanced, clear and offer the reader a modern and critical analysis of the literature on the subject of the magazine. Case reports, and lecture materials are also published for highlighting for practitioners new approaches to diagnosis and treatment of patients with metabolic disorders and obesity.